tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-5: Tirzepatide Bests Semaglutide in
Pay in 4 interest-free payments of $7.42 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-5: Tirzepatide Bests Semaglutide in](https://cdn.sanity.io/images/0vv8moc6/hcplive/342383d311b46707c21b2e340edef6682b09a798-2716x1810.jpg)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-5: Tirzepatide Bests Semaglutide in](https://static.wixstatic.com/media/1f382d_a99c0bceb3dd45a98c429d4c568dc8f5~mv2.png/v1/fill/w_280,h_180,al_c,q_85,enc_avif,quality_auto/1f382d_a99c0bceb3dd45a98c429d4c568dc8f5~mv2.png)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-5: Tirzepatide Bests Semaglutide in](https://www.researchgate.net/publication/374748518/figure/fig4/AS:11431281226179337@1709094754022/SURMOUNT-3-study-design-This-is-a-phase-3-multicenter-randomized-placebo-controlled.jpg)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SURMOUNT-5: Tirzepatide Bests Semaglutide in](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-023-02597-w/MediaObjects/41591_2023_2597_Fig1_HTML.png)

























